AXIOS

Written By Rob Cahill

Exclusive: Metabolic biotech Junevity doubles seed round to $20M

Junevity, a metabolism and neurodegeneration-focused biotech, has raised $10 million, doubling its seed round to $20 million, CEO John Hoekman tells Axios Pro exclusively.

Read more here.

Rob Cahill
Previous

WALL STREET JOURNAL
Next

PRESS RELEASE